10.12.24 -- Life Science Leader Best Of September

New research into Parkinson's disease is strengthening the connection between an unhealthy gut and brain disorders.

Shweta Maniar, Google’s global market leader for life sciences, spoke with Life Science Leader about how large and small biopharmaceutical companies are using AI to lower costs and expedite timelines.

As AI models become more deeply embedded across functions at biopharmaceutical companies, it is crucial to effectively manage the associated risks of data privacy and security, bias and fairness, regulatory compliance, and reliability and performance.

A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.

Explore AI's impact on TMF processes in this on-demand webinar. Gain clarity on AI's potential, key evaluation criteria, and practical applications for enhancing TMF health and inspection-readiness.

As you develop your future cell therapy drug, consider the risks and benefits of using autologous or allogeneic methods to best suit your development and manufacturing needs.